Cydan

Cydan is an orphan drug accelerator that was founded in 213 and is based in Cambridge MA. The firm has raised $26 million dollar to derisk therapeutic assets targeting orphan indications (excluding oncology). The firm looks to option/in-license assets and form subsidiary companies around them. Cydan then derisks the assets conducting all the necessary IND enabling activities. Cydan?s investment syndicate including NEA Pfizer Ventures Lundbeck Venturefonds Bay City Alexandria then has the option to fund the NEWCo Series A round to human proof of principle Cydan is also performing due diligence on companies that are interested in receiving investment from the company's syndicate. Cydan is currently considering pre-clinical and clinical assets worldwide.
Chris Adams
CEO 

Diamond BioFund Taiwan

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Winston Town
Vice President 
Haolin Sung
LinkedIn logo Director 

Easton Capital United States

Easton Capital Investment Group is a venture capital firm based in New York. Easton Capital invests broadly in the life science sector, and considers investment opportunities globally. The firm is likely to make 4-6 allocations in the next 6 months. Allocations typically vary from $250,000 to $5 million, in the form of equity or convertible debt. Allocations are typically made at the venture stage of development, but may be made in seed rounds if a company already has proof of their product's efficacy.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Lisa Rhoads
Managing Director 

Enso Ventures United States

Enso Ventures is a Venture Capital firm that was founded in 2010 and based in London with an additional office in New York. The firm is looking to provide equity capital to high growth companies in the life science space. The firm is currently interested in companies located in Europe, Russia and the US and is looking to make approximately 2-3 investments over the next 6-9 months.

Sergei Petukhov
Partner 

Excel Venture Management United States

Excel Venture Management is a venture capital firm that was founded in 2008 and is based in Boston, Massachusetts. The firm has managed one fund with committed capital of $125 million, and the firm is currently raising the second fund. Excel Venture Management seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $3 million to $ 5million. The firm plans to invest in 4-5 companies over the next 6-9 months and prefers to invest in companies based in US.

Year Founded
2008
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Eric Zimmerman
Kevin Liang

Genrich

Genrich is a Multi-Family office founded and based in Long Beach California with additional offices in New York Toronto and London. The firm is looking to make equity and venture debt investments into companies in the life science space ranging from $2-$2 million over the lifetime of the investment often set up in tranches. Ideal candidates will be located 2 hours driving distance from one of the firm?s offices Boston and Chicago will also be considered. The firm is actively seeking new investment opportunities.
John Nelson
Managing Director 

Golden Seeds

Golden Seeds is an investment group that was founded in 25 and is headquartered in New York with other offices in Boston Silicon Valley and Texas. The group currently invests out of the Golden Seeds angel network and the Golden Seeds venture funds. The group has managed 3 venture funds that are Golden Seeds Fund LP Golden Seeds Fund 2 LP and Innovate New York LP Fund. The Golden Seeds angel network has 32 members of which 1 are life science investors. Golden Seeds invests in companies with a female founder or CEO or with women in other C-level positions or with at least 1% of equity owned by women. Golden Seeds prefers to invest in companies with a valuation under $5 million, the group?s first-round equity investments generally range from $ .25 million to $2 million. The group invests in companies based across the US and Canada.
Bill Whitaker
Managing Director Co-Chair Life Science Section 

Green Park & Golf Ventures

Green Park & Golf Ventures (GPG) is a family office based in Dallas Texas. The firm was founded in 211 and is focused on healthcare companies. The firm makes seed venture and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $1K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.
Clay Heighten
Founding Partner 
JR Garcia
Principal 
Carl Soderstrom
Founding Partner 

Greenhouse Capital Partners United States

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.

Eric Desai
Principal 

H.I.G. BioVentures

H.I.G. BioVentures is the life science investment affiliate of H.I.G. Capital and has offices across the USA. H.I.G. BioVentures has assets under management of $4m and is investing from its second fund which closed at $268m in 212. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $2m over the life of an investment. While most of H.I.G. BioVentures? portfolio companies are US-based the firm will consider opportunities worldwide.
Enoch Kariuki
Vice President